Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)

Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a clinical and neuropsychiatric syndrome that is seen after chimeric antigen receptor T-cell (CAR-T) treatment, and it is mainly characterized by confusion, behavioral changes and language deficits. The current American Society of Transplantation and Cellular Therapy (ASTCT) guidelines recommend using the Immune Effector Cell Encephalopathy (ICE) score as an initial screening tool for the development of ICANS. However, the subjective nature of the scoring may hamper the precision of the patient assessment and potentially delay intervention. Recently, the Bispectral Electroencephalogram (BSEEG) was developed as an objective assessment tool for delirium. The BSEEG score has excellent detection performance for delirium (Shinozaki et al. Psychiatry Clin Neurosci 2018) and predicting patient outcomes, including hospital length of stay and mortality (Yamanashi et al. Br J Psychiatry 2021).

Thus, we aimed to prove whether the BSEEG could detect the onset of ICANS in patients treated with CAR-T therapy.

Methods: The BSEEG score was collected for 57 adult patients receiving CAR-T therapy for hematologic malignancies at Stanford Health Care between August 2023 and July 2024 using a portable, thumb-sized two-lead EEG device (ZA, ProAssist, Osaka, Japan). The score was calculated based upon the ratio of low-frequency (3Hz) to high-frequency (10Hz) power spectral density (PSD), such that a higher BSEEG score indicates the presence of more slow waves. ICE scores of 0-2 (ICANS grade 3 and 4) were used to define cases of severe ICANS. A baseline Montreal Cognitive Assessment (MoCA) test was performed for all patients. A Student's t-test was used to compare the averages of the BSEEG score in cases and controls.

Results: Mean age of our cohort was 64.9 years, 65% were Caucasians, 18% were Asians, 7% were Black and 4% were Hispanic. 65% had a diagnosis of lymphoma, 25% had multiple myeloma and 10% had acute lymphoblastic leukemia. The CAR-T therapies patients received were axicabtagene ciloleucel (n = 17), brexucabtagene autoleucel (n = 5), lisocabtagene maraleucel (n = 2), tisagenlecleucel (n = 4), ciltacabtagene autoleucel (n = 9), idecabtagene vicleucel (n = 4), others (n = 16). 32% (n = 18) developed all grade ICANS, of which 14% (n = 8) developed severe (grade 3 or 4) ICANS. There were no statistically significant differences in age between the severe ICANS cohort (n = 8) vs control (n = 49) (69.6 vs 64.0, p = 0.36), in sex (p = 0.13), in ethnicities (p = 0.76) or in baseline MoCA score (24.9 vs 25.5, p = 0.72). A total of 147 BSEEG recordings were obtained during their treatment course. The average of the highest recorded BSEEG scores during patient's hospital stay for severe ICANS cohort was 1.84 (SD = 0.33) vs 1.60 (SD = 0.23) in controls (p = 0.013). Furthermore, there was an inverse correlation between ICE score and BSEEG score (rho = -0.20, p = 0.017).

Conclusions: We report the potential usefulness of an easy-to-use, portable EEG device that could detect the development of ICANS in patients receiving CAR-T therapy. It could be employed as an objective test to complement the relatively subjective ICE score. Further investigations are needed to validate the BSEEG score as a predictive tool for ICANS, where preventative measures and prompt intervention could be used to improve patient outcomes.

Hamilton:Kite Pharma-Gilead: Membership on an entity's Board of Directors or advisory committees. Kennedy:Astellas: Consultancy. Mikkilineni:Legend Biotech: Consultancy, Other: advisory board at ASH December 2023; BiolineRx: Consultancy, Other: advisory board at ASH December 2023. Smith:A28 Therapeutics: Current holder of stock options in a privately-held company; CVS Caremark: Consultancy. Dahiya:Kite/Gilead, BMS, Incyte, Adaptive biotechonologies: Consultancy. Muffly:Jasper: Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Adaptive: Research Funding; Vor: Consultancy, Research Funding; Wugen: Research Funding; Cargo Therapeutics: Consultancy; Pfizer: Consultancy; Bristol Myers Squibb: Consultancy; Astellas: Consultancy; Autolus: Consultancy. Sidana:Novartis: Research Funding; Kite, A Gilead company: Consultancy; BiolineRx: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; Takeda: Consultancy; Regeneron: Consultancy; Abbvie: Consultancy; Pfizer: Consultancy; BMS: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy. Weng:Dren Bio: Other: Member of Data and Safety Monitoring Board . Miklos:Miltenyi: Consultancy, Research Funding; Juno Therapeutics: Consultancy; Fosun Kite Biotechnology: Honoraria; 2SeventyBio: Research Funding; Allogene: Research Funding; Adaptive Biotechnologies: Research Funding; Bristol Myers Squibb: Consultancy; Galapagos: Consultancy; Janssen: Consultancy, Patents & Royalties; Adicet: Research Funding; Kite, a Gilead Company: Consultancy, Other: Travel Support, Research Funding; Novartis: Consultancy. Shinozaki:Delight Health Inc: Other: Co-founder, Patents & Royalties: Patent for BSEEG technology.